Lipitor OTC Switch Would Force Pfizer To Clear Big Research Hurdles
This article was originally published in The Tan Sheet
Executive Summary
Pfizer would face major hurdles in research on consumers’ safe self-selection for FDA to approve an OTC switch of the firm’s cholesterol treatment Lipitor.
You may also be interested in...
OTC Switch “Blueprint” Could Help Regulatory Navigation – Researchers
Rx-to-OTC switch questions that FDA asked advisory committees over the past 10 years can help guide future sponsors to success, says the lead researcher in an analysis of the agency’s switch actions.
Pfizer Will Unload Nutrition Division, Keep Consumer Product Unit
Pfizer will divest or spin off its nutrition unit but the firm will keep its consumer product business and look into future OTC switches.
Pfizer Consumer Chief Sees Chronic Conditions In OTC Future
Future OTC switches of drugs for chronic conditions like high cholesterol could "fundamentally help" alter the health care environment and lower costs, says Pfizer Consumer Healthcare President Paul Sturman.